KRINTAFEL (tafenoquine)

SELF-ADMINISTRATION - ORAL

Indication for Prior Authorization:

  • Indicated for patients ≥ 16 years of age for the radical cure (prevention of relapse) of Plasmodium vivax malaria who are receiving appropriate antimalarial therapy for acute P. vivax infection.
  • Not indicated for the treatment of acute P. vivax malaria.

Patients must meet the following criteria for the indication(s) above:

  • Patient is 16 years of age or older, AND
  • Diagnosis of Plasmodium vivax malaria, AND
  • Prescribed by or in consultation with an infectious disease specialist, AND
  • Prescribed in combination with an appropriate antimalarial therapy (e.g. chloroquine) for acute P. vivax infection, AND
  • Does not exceed dose of 300 mg (two-150 mg tablets) as a single dose
  • Contraindication:
    • G6PD deficiency or unknown G6PD status

Dosing:

  • Oral: 300 mg as a single dose on the first or second day of the appropriate antimalarial therapy
  • Dose does not exceed 300 mg (two-150 mg tablets) as a single dose

Approval:

  • 1 treatment (2 tablets only)

Last review date: April 16, 2019

Rite Aid Pharmacy Patients: All Rite Aid pharmacies nationwide are closing! Please be on the lookout for information from Rite Aid pharmacies about their bankruptcy and store closures. Call your Rite Aid pharmacy for questions about your prescriptions and new pharmacy options. WHA is here to help as well. Contact Us via Phone